Management and outcome across the spectrum of high‐risk patients with myocardial infarction according to the thrmobolysis in myocardial infarction (TIMI) risk‐score for secondary prevention

Background Patients with myocardial infarction (MI) are at increased risk for recurrent cardiovascular events, yet some patients, such as the elderly and those with prior comorbidities, are particularly at the highest risk. Whether these patients benefit from contemporary management is not fully elu...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cardiology (Mahwah, N.J.) N.J.), 2021-11, Vol.44 (11), p.1535-1542
Main Authors: Grinberg, Tzlil, Bental, Tamir, Hammer, Yoav, Assali, Abid, Vaknin‐Assa, Hana, Wiessman, Maya, Perl, Leor, Kornowski, Ran, Eisen, Alon
Format: Article
Language:English
Subjects:
Angioplasty
Anticoagulants
Blood transfusions
Cardiovascular disease
Clinical Investigations
Clinical outcomes
Coronary vessels
Data collection
Diabetes
Disease prevention
Enzymes
Heart attacks
Heart failure
Hemoglobin
high‐risk populations
Hypertension
Kidney diseases
Medical imaging
Mortality
myocardial infarction
Patients
risk‐stratification
Standard deviation
temporal trends
Trends
Vein & artery diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Patients with myocardial infarction (MI) are at increased risk for recurrent cardiovascular events, yet some patients, such as the elderly and those with prior comorbidities, are particularly at the highest risk. Whether these patients benefit from contemporary management is not fully elucidated. Methods Included were consecutive patients with MI who underwent percutaneous coronary intervention (PCI) in a large tertiary medical center. Patients were stratified according to the thrombolysis in myocardial infarction (TIMI) risk score for secondary prevention (TRS2°P) to high (TRS2°P = 3), very high (TRS2°P = 4), or extremely high‐risk (TRS2°P = 5–9). Excluded were low and intermediate‐risk patients (TRS2°P 
ISSN:0160-9289
1932-8737
DOI:10.1002/clc.23715